다중 암 조기 발견 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Multi Cancer Early Detection Market, valued at USD 1.3 billion in 2023, is projected to grow at a CAGR of 14.8% from 2024 to 2032. Campaigns and educational initiatives by governments and non-profits have increased public awareness about the importance of early cancer detection. Data shows that early detection can improve survival rates by up to 90% for certain cancer types. Improving public awareness is driving the adoption of multi-cancer early-detection tests. Leading pharmaceutical and biotechnology companies are collaborating with diagnostic firms to develop and promote MCED tests.

These partnerships are crucial for introducing new technologies to the market and ensuring their widespread acceptance. By test type, NGS technology supports several gene panels and LDTs, enabling the rapid sequencing of numerous genes. Its high throughput, accuracy, and declining costs have established its dominance in the MCED market. These tools are applicable to a wide range of cancers, offering significant versatility in cancer diagnostics.

Their ability to identify multiple cancer types from a single test enhances their value in the MCED market. Companies developing gene panels and LDTs have secured a significant position in the diagnostics field. Their focus on R&D and strategic alliances in the pharmaceutical and biotech sectors solidifies their leadership in the MCED domain. Advancements in genomics and molecular biology continue to evolve gene panels and LDTs.

This ongoing innovation keeps these tools at the forefront of cancer detection and strengthens their position in the MCED market. The multi-cancer early detection market is segmented by end-use into hospitals, diagnostic laboratories, and other end-users. Hospitals dominated the market in 2023 with a market share of 48.2%. Patients frequently visit hospitals for routine health check-ups, diagnostics, and cancer screenings.

This makes hospitals ideal venues for integrating MCED tests into established healthcare workflows. Hospitals have multidisciplinary teams, including oncologists, pathologists, geneticists, and other specialists, who collaboratively interpret and apply MCED test results. This teamwork enhances early detection efforts and improves treatment planning. North America led the multi-cancer early detection market in 2023, generating revenues of USD 518.9 million.

Substantial investments in next-generation sequencing (NGS) and liquid biopsy technologies drive this dominance. A favorable regulatory landscape, highlighted by the FDA's breakthrough device designations for multiple MCED tests, streamlines their development and approval. Increased patient awareness and a growing demand for early cancer detection solutions further strengthen the region's leadership in the global multi-cancer early detection market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 High cancer detection rate coupled with growing demand for effective cancer tools
    • 3.2.1.3 Advancements in data analytics and artificial intelligence (AI) utilized in cancer screening
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of multi-cancer screening test
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Gene panel, LDT, & others
• 5.3 Liquid biopsy

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Diagnostic laboratories
• 6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
  • 7.3.7 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 AnPac Bio-Medical Science Co., Ltd.
• 8.2 Burning Rock Biotech Limited
• 8.3 EarlyDiagnostics
• 8.4 Elypta AB
• 8.5 EXACT SCIENCES CORPORATION
• 8.6 Freenome Holdings, Inc.
• 8.7 Genecast Biotechnology Co., Ltd.
• 8.8 Guangzhou AnchorDx Medical Co., Ltd.
• 8.9 GUARDANT HEALTH, INC.
• 8.10 Illumina, Inc. (GRAIL, Inc.)
• 8.11 Micronoma, Inc.
• 8.12 Oncocyte Corporation
• 8.13 Roche Holdings, Inc (FOUNDATION MEDICINE, INC.)
• 8.14 SeekIn Inc.
• 8.15 Singlera Genomics Inc